LIPO: Lipella Pharmaceuticals Inc. Stock

by  •  • Comments Off on LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.08
Enterprise Value ($M) 1.73
Book Value ($M) 1.46
Book Value / Share 1.21
Price / Book 2.11
NCAV ($M) 1.38
NCAV / Share 1.14
Price / NCAV 2.24

Profitability (mra)
Return on Invested Capital (ROIC) -2.79
Return on Assets (ROA) -1.19
Return on Equity (ROE) -1.36

Liquidity (mrq)
Quick Ratio 2.97
Current Ratio 2.97

Balance Sheet (mrq) ($M)
Current Assets 2.08
Assets 2.16
Liabilities 0.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
7 days ago 13D/A Kaufman Jonathan H 8.00 0.00
02-10 13D/A Chancellor Michael B 7.90
11-14 13G/A Huang Leaf 5.70 -87.50
11-14 13G/A Gruber Michele 3.90 -87.16

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REP
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 19,176 73,753 26.00
2025-03-06 2,185 27,724 7.88
2025-03-05 18,204 46,589 39.07
2025-03-04 4,340 53,724 8.08

(click for more detail)

Similar Companies
LEXX – Lexaria Bioscience Corp. LFVN – LifeVantage Corporation
LGVN – Longeveron Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io